Investigations have demonstrated the existence of a family of structurally related peptides, atrial (ANP), brain (BNP), and C-type (CNP) natriuretic peptides, that function in the integrated control of renal and cardiovascular function. ANP is a 28-amino acid peptide that is secreted from the atria and possesses natriuretic, vasoactive, and renin-inhibiting actions.1,2 BNP is a recently isolated 32-amino acid peptide, also found in the heart, that shares structural and biological similarity to ANP.3 CNP is a newly identified 22-amino acid peptide that also demonstrates structural similarity to the cardiac hormones ANP and BNP4 and, like ANP and BNP, has a 17-amino acid ring formed by a disulfide bond. Unlike these two previously identified cardiac peptides, CNP lacks the COOHterminal amino acid extension from the ring structure. ANP, BNP, and CNP decrease cardiac preload, but unlike ANP and BNP, CNP is not natriuretic.5 Whereas ANP and BNP have been localized to the heart, recent investigations have failed to detect CNP messenger RNA (mRNA) in the human myocardium,6 although small concentrations of CNP are detectable in the porcine myocardium.7 CNP was originally localized to the brain, but recent investigations have localized it to endothelial cells, consistent with a paracrine role for CNP in the control of vascular tone.8-10 Both ANP and BNP function biologically via a guanylate cyclase receptor (ANPR-A) that is highly expressed in endothelial cells." CNP functions via a separate guanylate cyclase receptor (ANPR-B) that is highly expressed in vascular smooth muscle. All three peptides are cleared and degraded intracellularly by a common clearance receptor (ANPR-C).1l Most recently, Nunez and coworkers12 have reported that mRNA transcripts for these three receptors are all detectable in rat and human heart, underscoring a potential role for all three natriuretic peptides as possible paracrine factors in modulation of cardiac contractility or cardiac reflexes.
In chronic congestive heart failure (CHF), plasma concentrations of ANP Mukoyama and coworkers18 reported the elevation of circulating BNP in humans with CHF. Our findings confirm these observations. In contrast to Mukoyama et al, however, our studies reveal that circulating BNP is not elevated in the early stages of ventricular dysfunction but rather is increased only in subjects with moderate and severe CHF. The difference between these two studies may be related to a greater separation of patients in our study, which used both evaluation of symptoms and assessment of ventricular function and/or the lack of detection of large-molecular-weight BNP with our assay. In contrast to circulating concentrations of BNP, atrial BNP concentrations were markedly increased in CHF. The higher atrial BNP in mild and severe CHF ( The plasma elevation of ANP in the absence of elevation of BNP may serve as a noninvasive marker for early asymptomatic ventricular dysfunction. This isolated elevation of ANP may contribute to the pathophysiological compensation of early ventricular dysfunction, as supported by studies in experimental CHF in which activation of ANP in acute CHF served to inhibit activation of the renin-angiotensin-aldosterone system and maintain sodium balance despite the stimulus of arterial hypotension.21 With chronic severe CHF, the renin-angiotensin system may escape from the inhibitory action of ANP, and both ANP and renin are recruited together. 32 The elevation of circulating BNP may be a marker for symptomatic CHF. The contribution of BNP to the regulation of cardiorenal function remains unclear, with recent studies demonstrating either an enhanced natriuretic action in CHF in humans33 or a markedly blunted renal and cardiovascular action to pharmacological concentrations of BNP in experimental CHF.34,35 CNP elevation, unlike ANP and BNP, is not characteristic of human CHF, although a possible paracrine role in the heart in CHF will need to be explored. The functional significance of a lack of increase in circulating CNP, a potent vasoactive peptide,36 remains to be defined.
In summary, the present investigations report for the first time circulating concentrations and cardiac tissue activity of the three structurally related cardiorenalacting peptides ANP, BNP, and CNP in human CHF. These studies support a differential regulation of their circulating and cardiac concentrations.
